Wednesday, February 10, 2010, 2:23PM AEST - The Australian Stockmarket closes in 1 hour and 42 minutes.
To create a watchlist or portfolio of shares, Register

Cumberland Pharmaceuticals, Inc. (CPIX)

 8:00AM AEST: 11.52 USD  Up 0.11 (0.96%)  
 MORE ON CPIX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Cumberland Pharmaceuticals Inc. (NasdaqNM:CPIX) Delayed quote dataEdit
Last Trade:11.52 USD
Trade Time: 8:00AM AEST
Change:Up 0.11 (0.96%)
Prev Close:11.41
Open:11.47
Bid:9.62 x 100
Ask:N/A
1y Target Est:20.67
Day's Range:11.30 - 11.66
52wk Range:11.30 - 17.75
Volume:33,737
Avg Vol (3m):41,384.1
Market Cap:231.94M
P/E (ttm):50.31
EPS (ttm):0.23
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m 
 Add CPIX to Portfolio   Download Data

 HEADLINES 
•Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
PR Newswire (Thu, Jan 21)
•After A Sluggish Year, VCs Eye Improvement
Investor's Business Daily (Sat, Jan 9)
•Caldolor(R) Data to Be Presented During Critical Care Conference in Miami Beach, Florida on January 12, 2010
PR Newswire (Wed, Jan 6)
•The Worst IPOs Of 2009
at Investopedia (Thu, Dec 17)
•2009 Year End Strategy: Look at CEFs and IPOs
at Seeking Alpha (Wed, Dec 16)
•Kristalose(R) Preferred by Patients With Chronic Constipation Compared to Similar Products in a Recent Study
PR Newswire (Wed, Dec 16)
•Worst IPOs of 2009: Biggest Stock Flops
at TheStreet.com (Wed, Dec 16)
•Cumberland Pharma signs South Korea Caldolor deal
AP (Thu, Dec 10)
•Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
PR Newswire (Thu, Dec 10)
•New Caldolor(R) (ibuprofen) Injection Data to Be Presented at 44th American Society of Health-System Pharmacists Meeting
PR Newswire (Fri, Dec 4)
•Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems
PR Newswire (Wed, Dec 2)
More Headlines for CPIX...
 ANALYST 
EPS Est (next year) (Dec-09) :0.20
EPS Est (in 2 years) (Dec-10) :0.48
Avg Rec (current)*:1.5
PEG Ratio:0.95
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Cumberland Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices